Publications

Featured Publications

Interleukin-18 Engineered For Resistance to IL-18 Binding Protein (IL-18BP) and Half-Life Extension to Enhance Its Therapeutic Potential

American Association for Cancer Research (AACR) Annual Meeting

calendar icon April 2024


>> View Poster

Generation of tumor targeted self-assembling split IL-12p35 and IL-12p40 subunits for the treatment of cancer

American Association for Cancer Research (AACR) Annual Meeting

calendar icon April 2024


>> View Poster

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1

American Society of Clinical Oncology (ASCO) Annual Meeting

calendar icon June 2022


>> View Presentation

All Publications

  • Filter by Indications

  • Filter by Clinical Study

Clinical Outcomes of Ovarian Cancer Patients Treated With ALKS 4230, a Novel Engineered Cytokine, in Combination With Pembrolizumab: ARTISTRY-1 Trial

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon April 2020


>> View Poster

ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy

Journal for ImmunoTherapy of Cancer

calendar icon March 2020


>> View Publication

ARTISTRY-2: A Phase 1/2 Study of Subcutaneously Administrated ALKS 4230 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2019


>> View Poster

Intravenous Administration of ALKS 4230 as Monotherapy and in Combination With Pembrolizumab in a Phase 1/2 Study of Patients With Advanced Solid Tumors

American Society of Clinical Oncology (ASCO) Annual Meeting

calendar icon May 2019


>> View Poster

Peripheral Blood Lymphocyte Response to High Dose IL2 in RCC

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2018


>> View Poster

Pharmacokinetics and Pharmacodynamic Effects of ALKS 4230, an Investigational Immunotherapeutic Agent, in Cynomolgus Monkeys After Intravenous and Subcutaneous Administration

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2018


>> View Poster

Safety, Pharmacokinetics, and Pharmacodynamic Effects of ALKS 4230 in Patients With Advanced Solid Tumors From the Ongoing Dose Escalation Portion of a First In Human (FIH) Study

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2018


>> View Poster

A Novel, Individualized Xenograft Model of Cancer Immunotherapy and Tumor Growth Inhibition by ALKS 4230

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2017


>> View Poster

A Phase 1 Trial of ALKS 4230, an Engineered Cytokine Activator of NK and Effector T Cells, in Patients with Advanced Solid Tumors

American Society of Clinical Oncology (ASCO) Annual Meeting

calendar icon June 2017


>> View Poster

First-In-Human Dose Selection for ALKS 4230, an Investigational Immunotherapeutic Agent

American Association for Cancer Research (AACR) Annual Meeting

calendar icon April 2017


>> View Poster

Efficacy of ALKS 4230, a Novel Immunotherapeutic Agent, in Murine Syngeneic Tumor Models Alone and in Combination with Immune Checkpoint Inhibitors

American Association for Cancer Research (AACR) Annual Meeting

calendar icon April 2017


>> View Poster

Characterization of the Pharmacodynamic Immune Response to a Novel Immunotherapeutic Agent, ALKS 4230, in Mice and Non-Human Primates

American Association for Cancer Research (AACR) Annual Meeting

calendar icon April 2017


>> View Poster